Fused heterocyclic compounds useful as kinase modulators

US7723336B2 · kind B2 · utility

Assignee

• Bristol-Myers Squibb Company · US

Inventors

• Wayne Vaccaro · Yardley, US
• Zhong Chen · Singapore, SG
• Dharmpal S. Dodd · Princeton, US
• Tram N. Huynh · Pennington, US
• James Lin · Lawrenceville, US
• Chunjian Liu · Pennington, US
• Christopher P. Mussari · Princeton, US
• John S. Tokarski · Princeton, US
• David R. Tortolani · Skillman, US
• Stephen T. Wrobleski · Whitehouse Station, US
• Shuqun Lin · Newtown, US

Key dates

• Filing date: Mar 21, 2007
• Grant date: May 25, 2010
• Expiry date: Oct 12, 2027

Classification

• Technology area (CPC A): Human Necessities
• CPC primary: A61P35/00
• WIPO field: Pharmaceuticals
• WIPO sector: Chemistry

Abstract

Compounds having the formula (I), and enantiomers, and diastereomers, pharmaceutically-acceptable salts, thereof,are useful as kinase modulators, including MK2 modulation, wherein one of E and F is a nitrogen atom and the other of E and F is a carbon atom, Z is N or CR3, and R1, R2, R3, X and Y are as defined herein.